EW — Edwards Lifesciences Balance Sheet
0.000.00%
Last trade - 00:00
- $51.73bn
- $50.75bn
- $6.00bn
- 90
- 16
- 81
- 66
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 1,517 | 1,403 | 1,467 | 1,215 | 1,645 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 599 | 603 | 665 | 699 | 837 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 2,984 | 3,091 | 3,181 | 3,096 | 4,036 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1,140 | 1,489 | 1,639 | 1,725 | 1,843 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 6,488 | 7,237 | 8,503 | 8,293 | 9,363 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 902 | 894 | 1,032 | 1,022 | 1,195 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 2,340 | 2,663 | 2,667 | 2,486 | 2,713 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 4,148 | 4,574 | 5,836 | 5,807 | 6,650 |
Total Liabilities & Shareholders' Equity | 6,488 | 7,237 | 8,503 | 8,293 | 9,363 |
Total Common Shares Outstanding |